Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients
- Alshalalfa, M.
- Verhaegh, G.W.C.T.
- Gibb, E.A.
- Santiago-Jimenez, M.
- Erho, N.
- Jordan, J.
- Yousefi, K.
- Lam, L.L.C.
- Kolisnik, T.
- Chelissery, J.
- Seiler, R.
- Ross, A.E.
- Karnes, R.J.
- Schaeffer, E.M.
- Lotan, T.T.
- Den, R.B.
- Freedland, S.J.
- Davicioni, E.
- Klein, E.A.
- Schalken, J.A.
DOIAbstract
BACKGROUND: Prostate cancer antigen 3 (PCA3) is a prostate cancer diagnostic biomarker that has been clinically validated. The limitations of the diagnostic role of PCA3 in initial biopsy and the prognostic role are not well established. Here, we elucidate the limitations of tissue PCA3 to predict high grade tumors in initial biopsy. RESULTS: PCA3 has a bimodal distribution in both biopsy and radical prostatectomy (RP) tissues, where low PCA3 expression was significantly associated with high grade disease (p/=8) with 55% sensitivity and high false negative rates; 42% of high Gleason (>/=8) samples had low PCA3. In RP, low PCA3 is associated with adverse pathological features, clinical recurrence outcome and greater probability of metastatic...
Add to ORKG